Table 4.
Trial/Follow-up | N | Mean (s.e.) | |
Clinical Trial 1 | |||
8 Weeks | None/Minor | 59 | 75.0 (2.3) |
Mild | 158 | 73.9 (1.5) | |
Moderate | 58 | 77.3 (2.4) | |
Severe | 13 | 74.3 (5.1) | |
Clinical Trial 3 | |||
4 Weeks | None/Minor | 39 | 75.7 (3.8) |
Mild | 20 | 69.2 (5.1) | |
Moderate | 72 | 72.4 (2.7) | |
Severe | 79 | 66.4 (2.6) | |
12 Weeks | None/Minor | 36 | 75.0 (3.8) * |
Mild | 16 | 70.8 (5.6) | |
Moderate | 66 | 71.3 (2.9) | |
Severe | 65 | 62.8 (2.9) | |
24 Weeks | None/Minor | 33 | 75.6 (4.3) |
Mild | 14 | 73.3 (6.4) | |
Moderate | 63 | 70.0 (3.1) | |
Severe | 69 | 66.3 (3.0) |
*p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline sleep disturbance score, and symptom resolution status.